Larimar Therapeutics, Inc. Common Stock LRMR
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $11.86 (+277.6% upside)
Key Stats
- Today's Range
- $3.12 – $3.20
- 50-Day Range
- $3.02 – $4.46
- 52-Week Range
- $2.71 – $6.42
- Volume
- 1.04 million shs
- Average Volume
- 1.22 million shs
- Market Cap
- $329.31 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.11%
- Days to Cover
- 1.00
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Related Stocks
Compare head-to-head: LRMR vs LLY·LRMR vs JNJ·LRMR vs ABBV·LRMR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.